… gene are associated with PD and many of these have been shown to increase LRRK2 activity. To associate clinical and pre-clinical outcomes with binding of a therapeutic agent to LRRK2, a target … LRRK2 Target Engagement Ligand …

… MJFF staff member Sam Fox channels Marty McFly with Back to the Future Part II hoverboard. Next October Marty McFly officially comes to the future. With the 30th anniversary of the Back … year, fans and engineers continue to dream about the gadgets that exist in the world Marty lands in on October 21, …

… continues for Northera, Chelsea Therapeutics ’ candidate to treat orthostatic hypotension in Parkinson’s and other … Those living with orthostatic hypotension —  a sudden drop in blood pressure when standing up, which can cause … not what Chelsea was hoping for, the door may not be completely closed on Northera.  The FDA has asked for …

… The protein alpha-synuclein has been linked to Parkinson’s disease (PD). The prevailing hypotheses state … neurons is considered a viable therapeutic option. However, we have compelling evidence that show that alpha-synuclein is …

… Parkinson’s disease (PD) develop untreatable cognitive symptoms due to changes in the brain’s cerebral cortex. These … in vulnerable nerve cells interferes with brain health. However, the relationships between alpha-synuclein, damaged … that networks of nerve cells in the cerebral cortex become dysfunctional because of damage caused by toxic …

… grant: Inhibition of Striatal-Enriched Phosphatase (STEP) to Improve Parkinson-Related Cognitive Dysfunction Promising Outcomes of Original Grant: Our original funded project was … Alzheimer's disease. There are also preliminary data that show an increase in STEP in a Parkinson's pre-clinical model, …